Prestige Consumer Healthcare Inc. — Form 10-Q Summary
Business context and period: Prestige develops, markets, sells and distributes over-the-counter healthcare products in North America and international markets. This report covers the first quarter of fiscal 2022, the three months ended June 30, 2021, compared with the same period in fiscal 2021. Dollar amounts are in millions unless noted.
Financial performance
- Revenue: Total revenue was $269.2, up 17.3% from $229.4. North American OTC revenue rose 15.1% to $242.4; International OTC revenue rose 43.0% to $26.8.
- Category trends: Eye & Ear Care increased 57.5% in North America and Gastrointestinal increased 41.0%. Women’s Health declined 3.3% and Oral Care declined 5.4% in North America. Management attributed strength in certain categories to increased travel and easing COVID-19 restrictions.
- Profit and margins: Gross profit increased 18.8% to $159.0; gross margin improved to 59.1% from 58.4%, primarily due to product mix. Operating income rose to $91.3 from $80.1. Net income increased to $57.8 from $43.7; diluted EPS was $1.14 versus $0.86.
- Expenses and contribution margin: Advertising and marketing expense increased to $39.4 from $27.8. Consolidated contribution margin, defined as gross profit less advertising and marketing, increased to $119.6 from $106.1, but declined as a share of revenue to 44.4% from 46.3%. General and administrative expense was $22.5, up from $19.9, mainly due to compensation costs.
- Interest and taxes: Net interest expense decreased to $15.1 from $21.9. Management cited lower average debt and a lower average borrowing cost (4.0% versus 5.1%). The effective tax rate was 24.4%, compared with 24.9%.
- Cash flow: Operating cash flow was $69.3, down from $75.2, reflecting increased working capital partly offset by higher net income. Investing cash outflow was $1.3, including $1.5 of capital expenditures. Financing provided $63.7, including $85.0 of revolver borrowings and $20.0 of term-loan repayments. Cash increased to $163.6 from $32.3.
- Debt and liquidity: Gross debt was $1.56 billion at June 30, including $85.0 outstanding on the revolver; $57.1 of revolver capacity remained. Cash was $163.6. The company reported compliance with its financial and restrictive covenants and stated it expected to remain compliant over the next 12 months. Its debt agreements include leverage, interest-coverage and fixed-charge requirements.
Material changes and notable events
- Revenue growth was broad across segments, with the International segment expanding faster; the mix of category performance remained uneven.
- Gross margin improved, but higher advertising and marketing spending reduced North American contribution margin as a percentage of segment revenue.
- After quarter-end, on July 1, 2021, Prestige completed its $230.0 cash acquisition of Akorn’s Consumer Health business, including TheraTears and other OTC brands. The purchase-price allocation was still in progress. The company funded the purchase using cash, additional revolver borrowings and proceeds from term-loan refinancing.
- Also on July 1, the company refinanced its term loans with $600.0 of new Term B-5 Loans, extending maturity to July 1, 2028. The disclosed rate option was LIBOR plus 2.00% (0.50% floor) or an alternative base rate plus 1.00%; required quarterly payments are 0.25% of principal.
Outlook, risks and contingencies
- Outlook: The filing does not provide specific revenue, earnings or margin guidance. Management said operating cash flow and existing credit facilities were expected to fund working capital and capital expenditures for the next 12 months, excluding acquisitions.
- Management commentary: The company reported solid consumer consumption and share gains across most brands in the quarter, along with increased demand in certain travel-related categories. It had not experienced material overall supply-chain disruption or a material negative COVID-19 impact to date, but emphasized continuing uncertainty.
- Key risks: COVID-19 and changing consumer demand; competition, retailer requirements and pricing pressure; dependence on major customers (Walmart represented 20.5% of gross revenue); reliance on third-party manufacturers and a primary U.S. distribution center; foreign-exchange and interest-rate exposure; acquisition integration and financing; and substantial debt. Goodwill and intangible assets are significant, and adverse operating assumptions could lead to impairment charges.
- Contingencies and unusual items: Management said reasonably possible losses from routine legal matters, after reserves, were not expected to have a material adverse effect. The company had begun terminating its U.S. qualified pension plan; approximately $52.1 of obligations were expected to be settled through lump sums and annuities, with the transaction expected to close in fiscal 2023. No distributions had been made by June 30.
Important facts for investors to verify
- Whether the post-quarter Akorn acquisition delivers expected growth and how the final purchase-price allocation affects goodwill, intangibles and future amortization.
- The post-refinancing debt balance, borrowing costs, leverage and remaining revolver capacity after funding the acquisition.
- Whether revenue and gross-margin gains persist as travel patterns and COVID-19-related category demand normalize, and whether higher marketing spending supports profitable growth.
- Customer and supplier concentration, supply-chain resilience, covenant headroom, and sensitivity to interest-rate and foreign-exchange changes.